Compare Five9 Inc (FIVN) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five9 Inc vs Pfizer Inc — how do they compare? Five9 Inc trades at $31.2 (market cap $2.44B), while Pfizer Inc trades at $26.32 (market cap $151.73B). The key difference: Pfizer Inc is far larger — about 62.2× Five9 Inc's market cap, and Pfizer Inc pays a 6.46% dividend while Five9 Inc pays none. Which is the better fit depends on your goals.
| FIVN | PFE | |
|---|---|---|
Market Cap | $2.44B | $151.73B |
Sector | Technology | Health |
52-Week High | $34.48 | $28.56 |
52-Week Low | $13.61 | $23.60 |
Enterprise Value | $2.59B | $203.22B |
Volume | — | 29,869,932 |
Dividend Yield | — | 6.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIVN trades at $31.37, down 9.02% in the past day but remains near its 52-week high. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings estimates in recent quarters. Revenue growth is accelerating, with 2025 revenue reaching $1.15 billion and net income turning positive at $39.42 million. Recent management appointments and AI-driven subscription growth provide operational tailwinds.
Outlook is positive given earnings beats and analyst consensus, but risks include high valuation multiples and negative cash flow trends. The stock offers growth potential but requires monitoring of debt levels and competitive pressures in the CX software space.
Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.
The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
